Silane-modified hydroxyapatite nanoparticles incorporated into polydioxanone/poly(lactide-co-caprolactone) creates a novel toughened nanocomposite with improved material properties and in vivo inflammatory responses
The interface tissue between bone and soft tissues, such as tendon and ligament (TL), is highly prone to injury. Although different biomaterials have been developed for TL regeneration, few address the challenges of the TL-bone interface. Here, we aim to develop novel hybrid nanocomposites based on...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006423002387 |
| _version_ | 1827815420482027520 |
|---|---|
| author | Behzad Shiroud Heidari Emma Muinos Lopez Peilin Chen Rui Ruan Ebrahim Vahabli Seyed Mohammad Davachi Froilán Granero-Moltó Elena M. De-Juan-Pardo Minghao Zheng Barry Doyle |
| author_facet | Behzad Shiroud Heidari Emma Muinos Lopez Peilin Chen Rui Ruan Ebrahim Vahabli Seyed Mohammad Davachi Froilán Granero-Moltó Elena M. De-Juan-Pardo Minghao Zheng Barry Doyle |
| author_sort | Behzad Shiroud Heidari |
| collection | DOAJ |
| description | The interface tissue between bone and soft tissues, such as tendon and ligament (TL), is highly prone to injury. Although different biomaterials have been developed for TL regeneration, few address the challenges of the TL-bone interface. Here, we aim to develop novel hybrid nanocomposites based on poly(p-dioxanone) (PDO), poly(lactide-co-caprolactone) (LCL), and hydroxyapatite (HA) nanoparticles suitable for TL-bone interface repair. Nanocomposites, containing 3–10% of both unmodified and chemically modified hydroxyapatite (mHA) with a silane coupling agent. We then explored biocompatibility through in vitro and in vivo studies using a subcutaneous mouse model. Through different characterisation tests, we found that mHA increases tensile properties, creates rougher surfaces, and reduces crystallinity and hydrophilicity. Morphological observations indicate that mHA nanoparticles are attracted by PDO rather than LCL phase, resulting in a higher degradation rate for mHA group. We found that adding the 5% of nanoparticles gives a balance between the properties. In vitro experiments show that osteoblasts' activities are more affected by increasing the nanoparticle content compared with fibroblasts. Animal studies indicate that both HA and mHA nanoparticles (10%) can reduce the expression of pro-inflammatory cytokines after six weeks of implantation. In summary, this work highlights the potential of PDO/LCL/HA nanocomposites as an excellent biomaterial for TL-bone interface tissue engineering applications. |
| first_indexed | 2024-03-11T23:59:53Z |
| format | Article |
| id | doaj.art-3350959f5c514827b88d1c54e12e8c73 |
| institution | Directory Open Access Journal |
| issn | 2590-0064 |
| language | English |
| last_indexed | 2024-03-11T23:59:53Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj.art-3350959f5c514827b88d1c54e12e8c732023-09-18T04:30:22ZengElsevierMaterials Today Bio2590-00642023-10-0122100778Silane-modified hydroxyapatite nanoparticles incorporated into polydioxanone/poly(lactide-co-caprolactone) creates a novel toughened nanocomposite with improved material properties and in vivo inflammatory responsesBehzad Shiroud Heidari0Emma Muinos Lopez1Peilin Chen2Rui Ruan3Ebrahim Vahabli4Seyed Mohammad Davachi5Froilán Granero-Moltó6Elena M. De-Juan-Pardo7Minghao Zheng8Barry Doyle9Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and the UWA Centre for Medical Research, The University of Western Australia, Perth, Australia; School of Engineering, The University of Western Australia, Perth, Australia; Australian Research Council Centre for Personalised Therapeutics Technologies, Australia; Corresponding author.Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and the UWA Centre for Medical Research, The University of Western Australia, Perth, Australia.Cell Therapy Area, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, SpainCentre for Orthopaedic Research, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia; School of Medicine, Monash University, VIC, Melbourne, AustraliaCentre for Orthopaedic Research, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, AustraliaHarry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and the UWA Centre for Medical Research, The University of Western Australia, Perth, Australia; School of Engineering, The University of Western Australia, Perth, AustraliaDepartment of Biology and Chemistry, Texas A&M International University, Laredo, TX, USACell Therapy Area, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, SpainHarry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and the UWA Centre for Medical Research, The University of Western Australia, Perth, Australia; School of Engineering, The University of Western Australia, Perth, AustraliaCentre for Orthopaedic Research, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia; Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, AustraliaHarry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and the UWA Centre for Medical Research, The University of Western Australia, Perth, Australia; School of Engineering, The University of Western Australia, Perth, Australia; Australian Research Council Centre for Personalised Therapeutics Technologies, Australia; British Heart Foundation Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, UKThe interface tissue between bone and soft tissues, such as tendon and ligament (TL), is highly prone to injury. Although different biomaterials have been developed for TL regeneration, few address the challenges of the TL-bone interface. Here, we aim to develop novel hybrid nanocomposites based on poly(p-dioxanone) (PDO), poly(lactide-co-caprolactone) (LCL), and hydroxyapatite (HA) nanoparticles suitable for TL-bone interface repair. Nanocomposites, containing 3–10% of both unmodified and chemically modified hydroxyapatite (mHA) with a silane coupling agent. We then explored biocompatibility through in vitro and in vivo studies using a subcutaneous mouse model. Through different characterisation tests, we found that mHA increases tensile properties, creates rougher surfaces, and reduces crystallinity and hydrophilicity. Morphological observations indicate that mHA nanoparticles are attracted by PDO rather than LCL phase, resulting in a higher degradation rate for mHA group. We found that adding the 5% of nanoparticles gives a balance between the properties. In vitro experiments show that osteoblasts' activities are more affected by increasing the nanoparticle content compared with fibroblasts. Animal studies indicate that both HA and mHA nanoparticles (10%) can reduce the expression of pro-inflammatory cytokines after six weeks of implantation. In summary, this work highlights the potential of PDO/LCL/HA nanocomposites as an excellent biomaterial for TL-bone interface tissue engineering applications.http://www.sciencedirect.com/science/article/pii/S2590006423002387Tendon enthesisInterface tissueNanocompositesHydroxyapatiteSilane modification |
| spellingShingle | Behzad Shiroud Heidari Emma Muinos Lopez Peilin Chen Rui Ruan Ebrahim Vahabli Seyed Mohammad Davachi Froilán Granero-Moltó Elena M. De-Juan-Pardo Minghao Zheng Barry Doyle Silane-modified hydroxyapatite nanoparticles incorporated into polydioxanone/poly(lactide-co-caprolactone) creates a novel toughened nanocomposite with improved material properties and in vivo inflammatory responses Materials Today Bio Tendon enthesis Interface tissue Nanocomposites Hydroxyapatite Silane modification |
| title | Silane-modified hydroxyapatite nanoparticles incorporated into polydioxanone/poly(lactide-co-caprolactone) creates a novel toughened nanocomposite with improved material properties and in vivo inflammatory responses |
| title_full | Silane-modified hydroxyapatite nanoparticles incorporated into polydioxanone/poly(lactide-co-caprolactone) creates a novel toughened nanocomposite with improved material properties and in vivo inflammatory responses |
| title_fullStr | Silane-modified hydroxyapatite nanoparticles incorporated into polydioxanone/poly(lactide-co-caprolactone) creates a novel toughened nanocomposite with improved material properties and in vivo inflammatory responses |
| title_full_unstemmed | Silane-modified hydroxyapatite nanoparticles incorporated into polydioxanone/poly(lactide-co-caprolactone) creates a novel toughened nanocomposite with improved material properties and in vivo inflammatory responses |
| title_short | Silane-modified hydroxyapatite nanoparticles incorporated into polydioxanone/poly(lactide-co-caprolactone) creates a novel toughened nanocomposite with improved material properties and in vivo inflammatory responses |
| title_sort | silane modified hydroxyapatite nanoparticles incorporated into polydioxanone poly lactide co caprolactone creates a novel toughened nanocomposite with improved material properties and in vivo inflammatory responses |
| topic | Tendon enthesis Interface tissue Nanocomposites Hydroxyapatite Silane modification |
| url | http://www.sciencedirect.com/science/article/pii/S2590006423002387 |
| work_keys_str_mv | AT behzadshiroudheidari silanemodifiedhydroxyapatitenanoparticlesincorporatedintopolydioxanonepolylactidecocaprolactonecreatesanoveltoughenednanocompositewithimprovedmaterialpropertiesandinvivoinflammatoryresponses AT emmamuinoslopez silanemodifiedhydroxyapatitenanoparticlesincorporatedintopolydioxanonepolylactidecocaprolactonecreatesanoveltoughenednanocompositewithimprovedmaterialpropertiesandinvivoinflammatoryresponses AT peilinchen silanemodifiedhydroxyapatitenanoparticlesincorporatedintopolydioxanonepolylactidecocaprolactonecreatesanoveltoughenednanocompositewithimprovedmaterialpropertiesandinvivoinflammatoryresponses AT ruiruan silanemodifiedhydroxyapatitenanoparticlesincorporatedintopolydioxanonepolylactidecocaprolactonecreatesanoveltoughenednanocompositewithimprovedmaterialpropertiesandinvivoinflammatoryresponses AT ebrahimvahabli silanemodifiedhydroxyapatitenanoparticlesincorporatedintopolydioxanonepolylactidecocaprolactonecreatesanoveltoughenednanocompositewithimprovedmaterialpropertiesandinvivoinflammatoryresponses AT seyedmohammaddavachi silanemodifiedhydroxyapatitenanoparticlesincorporatedintopolydioxanonepolylactidecocaprolactonecreatesanoveltoughenednanocompositewithimprovedmaterialpropertiesandinvivoinflammatoryresponses AT froilangraneromolto silanemodifiedhydroxyapatitenanoparticlesincorporatedintopolydioxanonepolylactidecocaprolactonecreatesanoveltoughenednanocompositewithimprovedmaterialpropertiesandinvivoinflammatoryresponses AT elenamdejuanpardo silanemodifiedhydroxyapatitenanoparticlesincorporatedintopolydioxanonepolylactidecocaprolactonecreatesanoveltoughenednanocompositewithimprovedmaterialpropertiesandinvivoinflammatoryresponses AT minghaozheng silanemodifiedhydroxyapatitenanoparticlesincorporatedintopolydioxanonepolylactidecocaprolactonecreatesanoveltoughenednanocompositewithimprovedmaterialpropertiesandinvivoinflammatoryresponses AT barrydoyle silanemodifiedhydroxyapatitenanoparticlesincorporatedintopolydioxanonepolylactidecocaprolactonecreatesanoveltoughenednanocompositewithimprovedmaterialpropertiesandinvivoinflammatoryresponses |